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OBJECTIVES: To determine the prevalence of glaucomatous risk
factors (RFs) in glaucoma patients in a managed-care practice.
METHODS: Retrospective review of medical records of 1189
glaucoma patients. Diagnosis and documentation information of
15 RFs reported to be associated with glaucoma progression
were collected. The 15 RFs included age >70, family history,
African American origin, high intraocular pressure (IOP),
increase cup/disc (C/D) ratio, poor visual ﬁeld score, disc hem-
orrhage, pseudoexfoliation sign, low central corneal thickness
(CCT), high myopia, cardiovascular disease, systemic hyperten-
sion, diabetes mellitus (DM), migraine headache, and
vasospasm. The average risk score for the population was cal-
culated using the predictive model based on 5 risk factors (age,
IOP, CCT, C/D ratio, VF score, and DM) derived from Medeiros
et al. (2005), where a higher score indicates greater risk.
RESULTS: A total of 1182 of 1189 patients for which medical
records were available had a clear diagnosis in the charts. Mean
age (63.0 ± 11.9 years) and the average IOP (18.3 ± 4.7 mm Hg)
was calculated. Average value of C/D ratio was 0.52 ± 0.18,
pattern standard deviation was 2.59 ± 1.99 dB, and CCT was
552 ± 34 microns. The glaucomatous RF with the highest inci-
dence was systemic hypertension (39.0%), followed by age >70
(27.2%), DM (23.6%), African American origin (23.0%), and a
family history of glaucoma (18.2%). An average risk score was
42 for this population. CONCLUSION: Three of the ﬁve most
prevalent glaucomatous RFs from this population were not
included in the predictive model. The prevalence of RFs and risk
scores may be compared with a non-glaucoma patient popula-
tion or a population of glaucoma patients without glaucomatous
RFs to determine the relative risk difference. Existing models for
calculating glaucoma risk scores do not consider several impor-
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OBJECTIVES: We measured increased non-vision cost for 
progression to visual loss due to glaucoma. METHODS: We 
analyzed a random 5% sample of Medicare beneﬁciaries
(1999–2003). Presence the ICD-9 code, 365.xx, in a 1999 claim
was considered evidence of glaucoma. Inclusion required sur-
vival from 1999–2003. Moderate visual loss was deﬁned as
severe impairment in the worst seeing-eye (ICD-9 > 369.60).
Severe visual loss was deﬁned as severe impairment in best
seeing-eye (ICD-9 369.10 to 369.41). Blindness was deﬁned as
near total to profound impairment in both eyes (ICD-9 369.0 to
369.09). We identiﬁed those who reported depression, injury and
living in long-term care settings. We report the mean total
medical costs for each group and the increased risk of depres-
sion or injury, and living in an institutional setting associated
with progression. RESULTS: In total, 57,664 beneﬁciaries were
reported as having glaucoma. 54,596 did not experience severe
impairment in either eye, while 3068 beneﬁciaries (5.3%)
reported severe impairment in at least one eye during the ﬁve
year period. Increased visual impairment was associated with
higher overall medical costs in 2003. Those who were blind had
the highest cost of those who did not progress ($11,568). Those
who progressed from glaucoma to blindness had the highest
overall cost ($16,109). Among those who progressed to vision
loss, progression to blindness had the highest incremental cost
($5510). Those who progressed to any vision loss were more
likely to be diagnosed with depression or injury, or to be in long-
term care or skilled nursing facility than those who did not,
including those who had visual impairment at the beginning 
of the period. CONCLUSION: Among people with glaucoma,
progression to loss of visual function in even a single eye 
leads to higher medical costs during progression. A substantial
portion of this cost is associated with avoidable conditions and
institutionalization.
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OBJECTIVES: The purpose of this study was to estimate the
total and incremental costs associated with antibiotic treatments
for acute otitis media (AOM). METHODS: Persons over age 18
were identiﬁed in the Marketscan databases July–December
2004. We identiﬁed AOM episodes for patients with claims for
ICD9 codes 381.0X, 381.4X, 382.0X and 382.9X. We then
identiﬁed the most frequently antibiotics prescribed as initial
treatment for an AOM episode. Logistic regression estimated a
propensity score for each patient; which was the predicted prob-
ability of using telithromycin. Patients were then matched
according to this probability. Exponential conditional means
models (ECM) were speciﬁed, controlling signiﬁcant variables
after the propensity score matching (demographics and comor-
bidities). These models allowed the incremental costs to be esti-
mated for treatment of a reference drug, telithromycin, relative
to other antibiotics. RESULTS: The most common initial antibi-
otic treatments compared to telithromycin for AOM (n = 243
episodes) were amoxicillin, azithromycin, cefdinir, cefprozil and
levoﬂoxacin, moxiﬂoxacin. The mean length of an AOM episode
was 8.1 to 13.0 days. Mean total expenditures among the
episodes was $196, with a range of $165 to $244. Multivariate
ECM models were ﬁtted and showed signiﬁcant incremental cost
reductions per episode associated with telithromycin relative to:
cefdinir (−$64, p < 0.001), cefprozil (−$65, p < 0.001) and clar-
ithromycin (−$47, p < 0.001). CONCLUSION: The results of
this study show that the costs differed among episodes of AOM
by the initiating antibiotic. Use of propensity score matching and
ECM regression controlled for intra-episode differences, so the
incremental costs differences may be attributed to other factors
such as disease severity. Although different antibiotics may be in
the same drug class, the choice of the initiating antibiotic for an
AOM episode in this adult population clearly had ﬁnancial
implications.
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